About Dezhan Healthcare Company

The company was established in January 1981 with the approval of the Foreign Investment Management Committee on June 23, 1980. In March 1998, it was approved by the China Securities Regulatory Commission, listed on the Shenzhen Stock Exchange in May, and a major asset restructuring was carried out in July 2016. Currently, it is a state-owned pharmaceutical listed company controlled by a state-owned enterprise directly supervised by the Autonomous Region's State-owned Assets Administration Commission. The company's main business is R&D, production and sales of pharmaceuticals. The main products include atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, famciclovir tablets, azathioprine tablets, colchicine tablets, hydroxyurea tablets, acetyl hexapeptide-8, taro peptide-1, snake-like peptide-1, blue copper peptide, palmitoyl tripeptide-1, small laid-back relaxation drinks, Confucian alcohol peptide lactic acid bacteria drinks, rice collagen peptide series food products, hemp skin care products Qianbaihui series essential oil products, etc. Corporate honors: National Key Torch Program, National Key New Product Plan, National Science and Technology Progress Second Prize, etc.